OCI-Ly19Homo sapiens (Human)Cancer cell line

Also known as: LY19, Ly19, OCILy19, OCILY19, OCILY-19, OCI Ly19, OCI-Ly 19, OCI-LY-19, OCI-LY19

🤖 AI SummaryBased on 12 publications

Quick Overview

Human B-cell lymphoma cell line for cancer research

Detailed Summary

OCI-Ly19 is a human B-cell lymphoma cell line derived from diffuse large B-cell lymphoma (DLBCL). It is widely used in research to study the molecular mechanisms of lymphoma, particularly focusing on the role of BCL-2 and its implications in drug resistance. This cell line has been utilized in studies examining the efficacy of BCL-2 inhibitors like venetoclax, highlighting its importance in understanding therapeutic resistance in aggressive B-cell lymphomas. OCI-Ly19 is also used to investigate genetic and molecular alterations associated with lymphomagenesis, providing insights into the complex pathways involved in tumor development and progression.

Research Applications

Study of BCL-2 function and drug resistanceInvestigation of B-cell lymphoma molecular mechanismsEvaluation of BCL-2 inhibitor efficacy

Key Characteristics

Expresses BCL-2 proteinUsed in studies of venetoclax resistanceRelevant for understanding DLBCL pathogenesis
Generated on 6/17/2025

Basic Information

Database IDCVCL_1878
SpeciesHomo sapiens (Human)
Tissue SourceBone marrow[UBERON:UBERON_0002371]

Donor Information

Age27
Age CategoryAdult
SexFemale

Disease Information

DiseaseDiffuse large B-cell lymphoma
LineageLymphoid
SubtypeDiffuse Large B-Cell Lymphoma, NOS
OncoTree CodeDLBCLNOS

DepMap Information

Source TypeDSMZ
Source IDACH-000124_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleNRASp.Gln61Lys (c.181C>A)UnspecifiedAcquired during resistance selection processPubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11,12
D13S317
11,12
D16S539
12
D18S51
14
D19S433
14,15
D21S11
30
D2S1338
17,19
D3S1358
15,16
D5S818
9,11
D7S820
12
D8S1179
14,15
FGA
20,23
Penta D
12,13
Penta E
12,15
TH01
6,7
TPOX
8,9
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.

Clin. Cancer Res. 24:3967-3980(2018).

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Pham L.V.

Oncotarget 9:346-360(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Tucker H.O.

Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016).

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.

Leuk. Lymphoma 57:1015-1020(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Marra M.A.

Blood 122:1256-1265(2013).

Genetic heterogeneity of diffuse large B-cell lymphoma.";

Dunson D.B., Dave S.S.

Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

Nature 463:88-92(2010).

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Robetorye R.S., Aguiar R.C.T.

Blood 113:6681-6690(2009).

p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.

Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.

Leuk. Lymphoma 19:165-171(1995).

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Quentmeier H., Drexler H.G.

Leukemia 10:142-149(1996).